The document discusses ICH guidelines for stability testing of drug substances and products. The ICH guidelines provide recommendations for conducting stability testing to establish recommended storage conditions and shelf lives. Key ICH guidelines covered include Q1A on stability testing of new drug substances and products, Q1B on photostability testing, Q1C on stability testing for new dosage forms, and Q1E on evaluation of stability data. The guidelines address good stability practices such as stress testing, selection of batches, testing frequency, storage conditions and evaluation of results.

1. Drug Stability: ICH guidelines for stability
testing of drug substances and drug
products
Presented BY,
Ehteshamul Haque
1422750
M.Pharm (QA)
Presented To,
Dr. Rina Das Mehta

2. CONTENT-
1. Introduction
2. Objective of Stability testing
3. Stability Testing Terminologies
ICH Q1 A (R2)
ICH Q1 B
ICH Q1 C
ICH Q1 D
ICH Q1 E

3. INTRODUCTION-
 ICH is the "International Conference on
Harmonization of Technical Requirements
for Registration of Pharmaceuticals for
Human Use".
 ICH is a joint initiative involving both
regulators and research-based industry
representatives of the EU, Japan and the US
in scientific and technical discussions of the
testing procedures required to assess and
ensure the safety, quality and efficacy of
medicines.

4. Objective of Stability Testing
 “……to provide evidence on how the
quality of a drug substance or drug
product varies with time under the
influence of a variety of environmental
factors such as temperature, humidity &
light, & enables recommended storage
conditions, re-test periods & shelf lives to
be established"

5. QI A
Stability testing Of new drug
substances and products (second revision)
QIB
Stability testing : photo stability testing Of new drug
substance and products.
QIC
Stability testing for new dosage forms
QID
Bracketing and matrixing designs for stability testing
ofdrug substances and products

6. ICH GUIDELINES TITLE
Q1A Stability testing Of new drug substances and
products (second revision)
Q1B Stability testing : photo stability testing Of
new drug substance and products.
Q1C Stability testing for new dosage forms
Q1D Bracketing and matrixing designs for stability
testing ofdrug substances and products
Q1E Evaluation ofstability data
Q1F StabilityDataTackagefor Registration
Application Climatic zone III A and IV.

7. Q1A: Stability Testing of New Drug
Substances and Products-
 General
 Stress Testing
 Selection of Batches
 Container Closure System
 Specification
 Testing Frequency
 Storage Conditions
 Stability Commitment
 Evaluation
 Statements/Labelling

8. GENERAL-
 Information on the stability of the drug
substance is an integral part of the systematic
approach to stability evaluation.
SIRFSSTESIING-
 Main tool that predict the stability problems.
 Foundation for developing and validating
analytical methods. For an API the following
approaches may be used:
 When available, it is acceptable to provide
relevant data published in the scientific
literature to support the identified
degradation pathways and products.

9. Q1B: PHOTOSTABILITYTESTING
OF NEW DRUG SUBSTANCES AND
PRODUCTS-
 Photo-stability testing studies include:
 (Single batch) (no photo-stability studies after
administration)
 Test on drug substance.
 Test on exposed drug product outside the immediate
pack.
 Test on drug product in the immediate pack.
 Test on drug product in the marketing pack.
 Light source-
 Option 1:Artificial daylight lamp combining both visible
& UV output similar to D65 & ID65.
 Option 2: Cool white fluorescent & near UV lamp(320-
400nm)

10. Q1C: Stability Testingfor New Dosage
Forms-
 This document is an annex to the ICH parent
stability guideline and addresses the
recommendations on what should be submitted
regarding stability of new dosage forms by the
owner of the original application, after the
original submission for new drug substances and
products
 A new dosage form is defined as a drug product
which is a different pharmaceutical product type,
but contains the same active substance as
included in the existing drug product approved by
the pertinent regulatory authority.

11. Q1D: (Bracketing and Mabixing Designsßr Stability
Testing ofNew Drug Substanœs andProducts)-
BRACKETING-
 It is the design Of a stability schedule such that only
samples on the extremes Of certain design factors, e.g.,
strength, package size, are tested at all time points as in
a full design.
 The design assumes that the stability of any
intermediate levels is represented by the stability Of
the extremes tested.Where a range Of strengths is to
be tested, bracketing is applicable if the strengths are
identical or very closely related in composition.
 e.g.: for a tablet range made with different compression
weights of a similar basic granulation. Bracketing can be
applied to different container sizes or different fills in
the same container closure system.

12. MATRIXING-
 It is the design Of a stability schedule such
that a selected subset of the total number of
possible samples for all factor combinations is
tested at a specified time point.
 At a subsequent time point, another subset of
samples for all factor combinations is tested.
 The design assumes that the stability of each
subset of samples tested represents the
stability of all samples at a given time point.

13. Q1E: EVALUATION OF STABILITY
DATA-
Data Presentation-
 Data for all attributes should be presented in an
appropriate format (e.g., tabular, graphical, narrative)
and an evaluation of such data should be included in
the application.
 The values of quantitative attributes at all time points
should be reported as measured (e.g., assay as percent
of label claim).
 If a statistical analysis is performed, the procedure
used and the assumptions underlying the model should
be stated and justified.
 A tabulated summary of the outcome of statistical
analysis and/or graphical presentation of the long-term
data should be included.

14. Q1F: Stability Data Packagefor Registration
Applications in Climatic Zones Ill and IV
 Describes harmonised global stability
testing requirements in order to facilitate
access to medicines by reducing the
number of different storage conditions.
 WHO conducted a survey amongst their
member states to find consensus on
300C/65% RH as the long term storage
conditions for hot-dry and hot-humid
regions.

15. THANKYOU